Featured Press Releases

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

MedaSystems secures additional seed financing to advance its AI-driven workflow platform, expanding access and supporting investigator-initiated studies

MedaSystems secures additional seed financing to advance its AI-driven workflow platform, expanding access and supporting investigator-initiated studies

  • 06 Mar 2025

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS),...

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Made Scientific and Sentinel BioTherapeutics Announce a Strategic Manufacturing Partnership to Advance the Phase I/II Allogeneic ePP Encapsulated Cell Therapy Program

Made Scientific and Sentinel BioTherapeutics Announce a Strategic Manufacturing Partnership to Advance the Phase I/II Allogeneic ePP Encapsulated Cell Therapy Program

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies

Sai Life Sciences afslutter fase II af produktionsblok 11 på Bidar-stedet i Indien og øger kapaciteten til 700 KL

Sai Life Sciences afslutter fase II af produktionsblok 11 på Bidar-stedet i Indien og øger kapaciteten til 700 KL

Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025
CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

  • CollPlant
  • 30 Sep 2025
Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

  • Corstasis Therapeutics Inc.
  • 29 Sep 2025
Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

  • BioArctic AB
  • 29 Sep 2025
At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

  • Bayer
  • 25 Sep 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.